Haselager MV[au] - Search Results

Year	Number of Results
2018	1
2020	2
2022	1
2023	3

1

The Therapeutic Potential of Targeting NIK in B Cell Malignancies.

Haselager MV, Eldering E. Haselager MV, et al. Front Immunol. 2022 Jul 12;13:930986. doi: 10.3389/fimmu.2022.930986. eCollection 2022. Front Immunol. 2022. PMID: 35911754 Free PMC article. Review.

2

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?

Haselager MV, Kater AP, Eldering E. Haselager MV, et al. Front Oncol. 2020 Oct 8;10:592205. doi: 10.3389/fonc.2020.592205. eCollection 2020. Front Oncol. 2020. PMID: 33134182 Free PMC article. Review.

3

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation.

Kielbassa K, Haselager MV, Bax DJC, van Driel BF, Dubois J, Levin MD, Kersting S, Svanberg R, Niemann CU, Kater AP, Eldering E. Kielbassa K, et al. Among authors: haselager mv. Leukemia. 2023 Jun;37(6):1268-1276. doi: 10.1038/s41375-023-01898-w. Epub 2023 Apr 26. Leukemia. 2023. PMID: 37100883 Free PMC article.

4

Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment.

Seip K, Jørgensen K, Haselager MV, Albrecht M, Haugen MH, Egeland EV, Lucarelli P, Engebraaten O, Sauter T, Mælandsmo GM, Prasmickaite L. Seip K, et al. Among authors: haselager mv. Cancer Lett. 2018 Dec 28;439:1-13. doi: 10.1016/j.canlet.2018.09.023. Epub 2018 Sep 18. Cancer Lett. 2018. PMID: 30240588

5

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival.

Haselager MV, van Driel BF, Perelaer E, de Rooij D, Lashgari D, Loos R, Kater AP, Moerland PD, Eldering E. Haselager MV, et al. Hemasphere. 2023 Aug 23;7(9):e938. doi: 10.1097/HS9.0000000000000938. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37637994 Free PMC article.

6

JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.

Haselager MV, Thijssen R, Bax D, Both D, De Boer F, Mackay S, Dubois J, Mellink C, Kater AP, Eldering E. Haselager MV, et al. Mol Oncol. 2023 Jun;17(6):1112-1128. doi: 10.1002/1878-0261.13364. Epub 2023 Feb 13. Mol Oncol. 2023. PMID: 36550750 Free PMC article.

7

Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.

Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, Tam C, Forconi F, Chiodin G, Brown JR, Dubois J, Kater AP, Eldering E. Haselager MV, et al. Blood. 2020 Dec 17;136(25):2918-2926. doi: 10.1182/blood.2019004326. Blood. 2020. PMID: 32603412 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year